Literature DB >> 11757954

Neurological complications of sepsis: critical illness polyneuropathy and myopathy.

E Hund1.   

Abstract

Sepsis may cause not only failure of parenchymal organs but can also cause damage to peripheral nerves and skeletal muscles. It is now recognized that sepsis-mediated disorders of the peripheral nerves and the muscle, called critical illness polyneuropathy (CIP) and critical illness myopathy, are responsible for weakness and muscle atrophy occurring de novo in intensively treated patients. CIP represents an acute axonal neuropathy that develops during treatment of severely ill patients and remits spontaneously, once the critical condition is under control. The course is monophasic and self-limiting. Among the critical illness myopathies, three main types have been identified: a non-necrotizing "cachectic" myopathy (critical illness myopathy in the strict sense), a myopathy with selective loss of myosin filaments ("thick filament myopathy") and an acute necrotizing myopathy of intensive care. Clinical manifestations of both critical illness myopathies and CIP include delayed weaning from the respirator, muscle weakness, and prolonging of the mobilization phase. The pathogenesis of these neuromuscular complications of sepsis is not understood in detail but most authors assume that the inflammatory factors that mediate systemic inflammatory response and multiple organ failure are closely involved. In thick filament myopathy and acute necrotizing myopathy, administration of steroids and neuromuscular blocking agents may act as triggers. Specific therapies have not been discovered. Stabilization of the underlying critical condition and elimination of sepsis appear to be of major importance. Steroids and muscle relaxants should be avoided or administered at the lowest dose possible.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11757954     DOI: 10.1007/s004150170043

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  31 in total

1.  Optimizing outcomes for older patients treated in the intensive care unit.

Authors:  E Wesley Ely
Journal:  Intensive Care Med       Date:  2003-07-17       Impact factor: 17.440

Review 2.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

Review 3.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

4.  Critical illness polyneuropathy following childhood appendicitis.

Authors:  D Mullassery; A Curran; P D Losty
Journal:  Pediatr Surg Int       Date:  2008-07-30       Impact factor: 1.827

5.  Review of Critical Illness Myopathy and Neuropathy.

Authors:  Starane Shepherd; Ayush Batra; David P Lerner
Journal:  Neurohospitalist       Date:  2016-08-23

Review 6.  Critical illness polyneuropathy and myopathy in the intensive care unit.

Authors:  Wolfgang Zink; Rainer Kollmar; Stefan Schwab
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

7.  Neuregulin-1β modulates myogenesis in septic mouse serum-treated C2C12 myotubes in vitro through PPARγ/NF-κB signaling.

Authors:  Li Liu; Xueru Liu; Yiping Bai; Ni Tang; Jie Li; Yingying Zhang; Jiali Wu; Xiaobin Wang; Jicheng Wei
Journal:  Mol Biol Rep       Date:  2018-09-03       Impact factor: 2.316

8.  [Critical illness myopathy and neuropathy (CRIMYN). Electroneurographic classification].

Authors:  P Baum; S Bercker; T Villmann; J Classen; W Hermann
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

9.  Risk factors for critical illness polyneuromyopathy.

Authors:  J Bednarík; P Vondracek; L Dusek; E Moravcova; I Cundrle
Journal:  J Neurol       Date:  2005-03-30       Impact factor: 4.849

10.  Chronic Escherichia coli infection induces muscle wasting without changing acetylcholine receptor numbers.

Authors:  Christiane G Frick; Heidrun Fink; Maria L Gordan; Barbara Eckel; J A Jeevendra Martyn; Manfred Blobner
Journal:  Intensive Care Med       Date:  2007-10-20       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.